Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Alkali or alkaline earth chloride
Patent
1995-11-06
1998-09-29
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Alkali or alkaline earth chloride
A61K 3314
Patent
active
058143475
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to therapcutic compositions for use in the treatment of virus-induced cutaneous infections.
BACKGROUND OF THE INVENTION
A number of viral infections give rise to cutaneous lesions which can be painful, persistent and resistant to treatment. Complete healing requires the inhibition of viral replication and the regrowth of cutaneous tissue without scar formation. Examples of such viral infections include those produced by herpes virus--the most widely distributed viruses in human beings with some estimates suggesting that 60% of the population are affected. Infection with this virus remains sub-clinical and symbiotic in the cells of the host. However, this can be disturbed by intercurrent infections (e.g. the common cold and even, in some subjects, exposure to sunlight). There then develop typical herpetic vesicles especially around the mucocutaneous junction of lips and face. The genitals may be infected, the exudation from cutaneous lesions being especially infective and containing the virus in large amounts. A serious complication of cutaneous lesions is ocular involvement since this may lead to dendritic ulceration with scarring and impairment of vision. Zoster is also a virally induced lesion in which infective vesicles form.
SUMMARY OF THE INVENTION
According to a first aspect of the present invention there is provided a therapeutic composition for the treatment of virus-induced cutaneous infections, the composition comprising a first material for blocking viral DNA replication and a second finely divided material which absorbs exudated fluid from vesicles.
According to a second aspect of the present invention there is provided the use of a first material for blocking viral DNA replication and a second finely divided material which absorbs exudated fluid from vesicles for the manufacture of a medicament for the treatment of virus-induced cutaneous infections.
The preparations of the present invention, when applied to cutaneous lesions, have three co-operative effects: from vesicles, restricting spreading,
The material for blocking DNA replication may be an organic or inorganic compound known to possess this function. Most preferably the material is a lithium salt (with an organic or inorganic acid) since such materials are simple and free from side effects. Examples of suitable lithium salts are halide salts (particularly chloride, bromide and iodide) as well as the acetate, lactate, and succinate salts. Further more, lithium salts with polymeric anions (e.g. such as based on alginic acid or carboxymethyl cellulose) may be used. Organic materials which may be used include 5-iodo-2'-deoxyuridine and may if desired be used in conjunction with a lithium salt.
The material for absorbing exudated fluid from vesicles may for example be calcium carbonate, talc or a clay. It is however more preferred that the material is silica or a silicate. These latter materials are highly absorptive and immobilise absorbed exudate.
As mentioned above the second material for absorbing exudated fluid is used in finely divided form, preferably having a surface area of at least 1 m.sup.2 g.sup.-1 more preferably at least 100 m.sup.2 g.sup.-1. The average particle size of the material is preferably less than 30 microns, more preferably less than 10 microns, and most preferably less than 1 micron (e.g. colloidal size).
A preparation in accordance with the first aspect of the invention may, for example, comprise up to 60% by weight of the material for absorbing exudate. The amount by weight of the material for blocking viral DNA replication will generally (but not necessarily) be less than that of the exudate absorbing material and will typically (but again not necessarily) be less than 5% by weight, e.g. less than 1% by weight. The composition will generally also incorporate a pharmaceutically acceptable vehicle, e.g. water.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
Preferred compositions in accordance with the invention comprise silica and a compound of lithium. Silica (SiO.sub.2. nH.sub.2
REFERENCES:
patent: 3639625 (1972-02-01), Sherwin
Martindale, The Extra Pharmacopoeia, Thirteenth Edition, London, The Pharmaceutical Press, 1993, p. 1221, col. 2, lines 32-38.
Buchan, A.; Randall, S.; Hartley, C.E.; Skinner, G.R.B.; and Fuller, A; Effect of lithium salts on the replication of viruses and non-viral microorganisms; Lithium: Inorganic Pharmacology and Psychiatric Use, Proceedings of the 2nd British Lithium Congress held at Wolverhampton Polytechnic, Sep. 6-9, 1987.
ABEQ US 5223271 A. UPAB, 93. Nov. 16.
Chemical Abstracts 107:12 1107 (1985). Biener.
Browning Clifford W.
Fay Zohreh
Keele University
LandOfFree
Therapeutic compositions containing a lithium compound and silic does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic compositions containing a lithium compound and silic, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compositions containing a lithium compound and silic will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-684327